Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...

It’s true that we’ve come a long way in recent years when it comes to treating multiple myeloma. More therapies are being developed, to the point where somebody diagnosed now is likely to have ...

New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, prognosis, and therapeutic management of multiple myeloma. This new study in ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens. Adding monoclonal antibodies like Darzalex to standard treatments improves ...

About 6,000 people in the UK are diagnosed with multiple myeloma each year. The new time-saving test is intended for people with MGUS (Monoclonal Gammopathy of Unknown Significance), a precursor ...

Multiple myeloma is the second most common blood cancer after lymphoma in Korea, and it is a more common disease than expected. As of 2022, about 2000 people were newly diagnosed with multiple ...

April 14, 2025: Birmingham researchers have received £230k of translational funding from Cancer Research Horizons to develop a prototype for a new test to monitor people at risk of developing the ...

About 6,000 people in the UK are diagnosed with multiple myeloma each year. The new time-saving test is intended for people with MGUS (Monoclonal Gammopathy of Unknown Significance), a precursor ...

has dosed the 19th patient in its ongoing Phase 2 clinical trial evaluating GPC-100 (burixafor), a small molecule CXCR4 inhibitor, for the mobilization of stem cells in multiple myeloma (MM ...